SAN MATEO, Calif., March 12, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, ...
Latest Data from Phase I/II Study Reported in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and Published Concurrently in Nature Medicine VT3989 Achieves 32% ...
Study finds Hippo pathway aberrantly activated in NPH1 models, unveiling Kibra as a potential target
Nephronophthisis (NPH) is a recessive cystic kidney disease responsible for 10% to 20% of pediatric end-stage renal disease cases. NPHP1 (nephrocystin 1) is the most frequently implicated among over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback